Glenmark Pharmaceuticals Ltd
GLEN.BO- Latest Trade
- trading lower371.1INR
- -10.3
- 2.70%
- As of Jan 30 2023. Values delayed up to 15 minutes
- Day Range
- 369.50 - 383.00
- 52-Week Range
- 348.90 - 512.70
- Previous Close
- 381.40
- Open
- 380.55
- Volume
- 53,020.00
- 3 Month Average Trading Volume
- 21.85
- Shares Out (Mil)
- 282.17
- Market Cap
- 107,576.60
- Forward P/E
- 10.47
- Dividend Yield
- 0.66
Key Statistics
2.35294118 mean rating - 17 analysts
- P/E Excl. Extra Items (TTM)
- 12.96
- Price To Sales (TTM)
- 0.87
- Price To Book (Quarterly)
- 1.12
- Price To Cash Flow (Per Share TTM)
- 7.39
- Total Debt/Total Equity (Quarterly)
- 44.29
- Long Term Debt/Equity (Quarterly)
- 38.75
- Return On Investment (TTM)
- 7.23
- Return On Equity (TTM)
- 5.21
2021 (millions USD)
About Glenmark Pharmaceuticals Ltd (GLEN.BO)
Company Information
Glenmark Pharmaceuticals Limited is a global pharmaceutical company. The Company is primarily engaged in the business of developing, manufacturing and marketing of pharmaceutical products. It focuses on manufacturing products across therapeutic areas of respiratory, dermatology and oncology. It is involved in development of new chemical entities (NCEs) and new biological entities (NBEs). Its business segments include India, North America, Europe and Rest of the world. It is focused on developing and marketing branded and generic formulations. Its products include FabiFlu, Ryaltris and Remo (Remogliflozin etabonate). Its FabiFlu is an antiviral medication to treat mild to moderate COVID-19. Its Ryaltris is a fixed-dose combination nasal spray of an antihistamine (olopatadine hydrochloride 665 microgram) and a steroid that treats symptoms associated with seasonal, as well as perennial allergic rhinitis. Its Remo is a sodium-glucose transport-2 (SGLT2) inhibitor for the type 2 diabetes.
Address
B D S Marg Chakala, Off Western Express Highway Andheri (E),MUMBAI,
400099
India
Industry
Biotechnology & Drugs
Executive Leadership
- Glenn Mario Saldanha
- Executive Chairman of the Board, Chief Executive Officer, Managing Director
- V. S. Mani
- Global Chief Financial Officer, Executive Director
- Harish Kuber
- Compliance Officer, Company Secretary
- Cherylann Pinto
- Executive Director - Corporate Services
- Blanche E. Saldanha
- Non-Executive Director
- Dipankar Bhattacharjee
- Non-Executive Independent Director
- Rajesh V. Desai
- Non-Executive Independent Director
- Sridhar Gorthi
- Non-Executive Independent Director
- Devendra Raj Mehta
- Non-Executive Independent Director
- Bernard Munos
- Non-Executive Independent Director
- Sona Saira Ramasastry
- Non-Executive Independent Director
- Brian William Tempest
- Non-Executive Independent Director
Financials
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,924.10 | 0.27% |
| Copper | 781.65 | 0.21% |
| Brent Crude Oil | 85.93 | 0.84% |
| CBOT Soybeans | 1,524.00 | 0.96% |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,037.27 | 0.82% |
| Euro STOXX 50 | 4,152.38 | 0.61% |
| FTSE 100 | 7,777.14 | 0.15% |
| Nikkei 225 | 27,433.40 | 0.19% |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes